254 related articles for article (PubMed ID: 8813597)
1. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
Taniguchi H; Yazaki N; Endo T; Nagasaki M
Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini.
Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M
Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M
Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini.
Akiyama T; Otsuki M
Pancreas; 1994 May; 9(3):324-31. PubMed ID: 8022754
[TBL] [Abstract][Full Text] [Related]
7. Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
Br J Pharmacol; 1992 May; 106(1):61-6. PubMed ID: 1504732
[TBL] [Abstract][Full Text] [Related]
8. The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.
Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
Br J Pharmacol; 1995 Jan; 114(2):339-48. PubMed ID: 7881733
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
[TBL] [Abstract][Full Text] [Related]
10. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557
[TBL] [Abstract][Full Text] [Related]
11. Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists.
Singh L; Field MJ; Hill DR; Horwell DC; McKnight AT; Roberts E; Tang KW; Woodruff GN
Eur J Pharmacol; 1995 Nov; 286(2):185-91. PubMed ID: 8605955
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
Ballaz S; Barber A; Fortuño A; Del Río J; Martin-Martínez M; Gómez-Monterrey I; Herranz R; González-Muñiz R; García-López MT
Br J Pharmacol; 1997 Jun; 121(4):759-67. PubMed ID: 9208145
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitory effect of a new proglumide derivative, loxiglumide, on CCK action in isolated rat pancreatic acini].
Fujii M; Otsuki M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):77-82. PubMed ID: 2471851
[TBL] [Abstract][Full Text] [Related]
14. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
Gully D; Fréhel D; Marcy C; Spinazzé A; Lespy L; Neliat G; Maffrand JP; Le Fur G
Eur J Pharmacol; 1993 Feb; 232(1):13-9. PubMed ID: 7681406
[TBL] [Abstract][Full Text] [Related]
15. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
Boyle SJ; Tang KW; Woodruff GN; McKnight AT
Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
Chang RS; Lotti VJ
Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
[TBL] [Abstract][Full Text] [Related]
17. [Effect of cholecystokinin and its antagonists lorglumide, devazepide, and L-365,260 on gastrointestinal motility in rats].
Wang SX
Zhongguo Yao Li Xue Bao; 1993 Sep; 14(5):443-6. PubMed ID: 8010038
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
Louie DS; Liang JP; Owyang C
Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681
[TBL] [Abstract][Full Text] [Related]
19. CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor.
Yule DI; Williams JA
Peptides; 1994; 15(6):1045-51. PubMed ID: 7527529
[TBL] [Abstract][Full Text] [Related]
20. Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists.
Huang SC; Zhang L; Chiang HC; Wank SA; Maton PN; Gardner JD; Jensen RT
Am J Physiol; 1989 Jul; 257(1 Pt 1):G169-74. PubMed ID: 2473653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]